4.8 Review

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Journal

FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.701951

Keywords

ocular immune-related adverse events; immune checkpoint inhibitors; lung cancer; ophthalmoplegia; uveitis; dry eye

Categories

Funding

  1. Natural Science Foundation of China [82070954]
  2. Applied Basic Research Programs of Science and Technology Commission Foundation of Sichuan Province [19YYJC0790]
  3. Innovative Spark Grant of Sichuan University [2018SCUH0062]

Ask authors/readers for more resources

This study comprehensively illustrated the clinical characteristics, diagnosis, and management of immune checkpoint inhibitor (ICI)-related ocular immune-related adverse events (irAEs) in lung cancer patients based on 79 reported cases. Ophthalmoplegia, uveitis, and dry eye were the most common ICI-related ocular irAEs, with ophthalmoplegia having the highest mortality rate. Ethnicity and the type of ICIs significantly influenced the distribution of ocular irAEs, with early onset and worse prognosis features observed in ICI-related ophthalmoplegia.
Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have become increasingly popular in the treatment of lung cancer. Researchers have recognized ocular immune-related adverse events (irAEs) secondary to ICIs because of their vision-threatening characteristics. However, they are incompletely characterized and no studies have reported the ICI-related ocular irAEs in lung cancer. Therefore, we aimed to comprehensively illustrate the clinical characteristics, contributory factors, diagnosis, and management of ICI-related ocular irAEs in lung cancer, based on previously reported 79 patients. Ophthalmoplegia (40.51%), uveitis (20.25%), and dry eye (17.72%) were the most common ICI-related ocular irAEs in lung cancer. Ptosis was the most common (36.71%) and the highest mortality (23.33%) of ophthalmoplegia. Patients in Asia and patients who underwent combination therapy with programmed cell death-1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors demonstrated significantly higher frequency of ophthalmoplegia than other ocular irAEs. Most ICI-related ophthalmoplegia and uveitis in lung cancer were observed in the first 10 weeks following the initiation of ICIs. Furthermore, the onset time of dry eye and other ocular irAEs was much longer. In addition, 92.31% of the patients with ocular irAEs other than ophthalmoplegia could be remised. In conclusion, ocular irAEs secondary to ICIs in lung cancer are non-negligible, particularly ophthalmoplegia. Ethnicity and the type of ICIs play important roles in the distribution of ocular irAEs. ICI-related ophthalmoplegia in lung cancer presented with early onset and worse prognosis features, thus necessitating further attention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available